ArfGAP with GTPase domain, ankyrin repeat and PH domain 13, pseudogeneGenealiases: CTGLF9P · bA548K23.1
Q-omics provides the consensus-scored AGAP13P profile across patient tissues and cancer cell-line models. AGAP13P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AGAP13P is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, AGAP13P RNA expression shows 16,595 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where AGAP13P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGAP13P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGAP13P survival associations across molecular data types. AGAP13P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGAP13P RNA expression–survival associations across cancer types. High AGAP13P expression shows unfavorable associations in KIRC and ACC, but favorable associations in KIRP, HNSC, BLCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AGAP13P RNA expression.
This table summarizes AGAP13P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AGAP13P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGAP13P shows lower tumor expression in BRCA and THCA and higher tumor expression in KIRC, KIRP, PRAD and COAD. The KIRC box plot shows higher AGAP13P RNA expression in tumor versus normal tissue (log2 FC = +0.347, t-test p < 0.001).
This table shows molecular features associated with AGAP13P in patient tissues and cancer cell lines. In patient samples, AGAP13P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
